

# D George Wyse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11340878/publications.pdf>

Version: 2024-02-01

120  
papers

10,400  
citations

61857

43  
h-index

32761

100  
g-index

121  
all docs

121  
docs citations

121  
times ranked

7037  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2667-2677.	13.9	1,421
2	Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. <i>Circulation</i> , 2004, 109, 1509-1513.	1.6	1,105
3	Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial) Tj ETQq1 1 0.784314 rgtBT /Overlock 10 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Electrophysiology. <i>Circulation</i> , 2001, 104, 2118-2150.	1.6	844
4	The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 474-480.	2.1	747
5	Prevention of Atrial Fibrillation. <i>Circulation</i> , 2009, 119, 606-618.	1.6	446
6	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1847-1948.	0.8	313
7	Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation. <i>Circulation</i> , 2008, 117, 1518-1525.	1.6	311
8	Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS. <i>Heart Rhythm</i> , 2011, 8, 1416-1423.	0.3	296
9	Overview of endpoints in atrial fibrillation studies. <i>Heart Rhythm</i> , 2004, 1, 3-7.	0.3	248
10	A Randomized Clinical Trial of the Noninvasive and Invasive Approaches to Drug Therapy of Ventricular Tachycardia. <i>New England Journal of Medicine</i> , 1987, 317, 1681-1687.	13.9	197
11	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1371-1392.	0.8	195
12	Lone Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1715-1723.	1.2	177
13	Atrial Pacing Periablation for Prevention of Paroxysmal Atrial Fibrillation. <i>Circulation</i> , 1999, 99, 2553-2558.	1.6	170
14	Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1140-1150.	1.2	165
15	Incidence of Newly Detected Atrial Arrhythmias via Implantable Devices in Patients With a History of Thromboembolic Events. <i>Stroke</i> , 2010, 41, 256-260.	1.0	159
16	Functional Status in Rate- Versus Rhythm-Control Strategies for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1891-1899.	1.2	158
17	Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. <i>Europace</i> , 2012, 14, 804-809.	0.7	149
18	Validation of a New Simple Scale to Measure Symptoms in Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 218-224.	2.1	145

#	ARTICLE	IF	CITATIONS
19	Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. <i>Europace</i> , 2006, 8, 935-942.	0.7	141
20	Detection of Previously Undiagnosed Atrial Fibrillation in Patients With Stroke Risk Factors and Usefulness of Continuous Monitoring in Primary Stroke Prevention. <i>American Journal of Cardiology</i> , 2012, 110, 1309-1314.	0.7	140
21	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. <i>Journal of the American College of Cardiology</i> , 2008, 51, 865-884.	1.2	130
22	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1796-1802.	1.2	129
23	Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. <i>Journal of the American College of Cardiology</i> , 1991, 18, 145-151.	1.2	118
24	Randomized Crossover Comparison of DDDR Versus VDD Pacing After Atrioventricular Junction Ablation for Prevention of Atrial Fibrillation. <i>Circulation</i> , 2000, 102, 736-741.	1.6	117
25	Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	113
26	Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2004, 141, 653.	2.0	102
27	ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation. <i>Circulation</i> , 2004, 109, 3223-3243.	1.6	101
28	Chelation Therapy for Ischemic Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 481.	3.8	96
29	Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2010, 106, 1277-1283.	0.7	96
30	Atrial Fibrillation: A Perspective. <i>Circulation</i> , 2004, 109, 3089-3095.	1.6	89
31	International Consensus on Nomenclature and Classification of Atrial Fibrillation: A Collaborative Project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 443-445.	0.8	81
32	A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF Scale. <i>Canadian Journal of Cardiology</i> , 2006, 22, 383-386.	0.8	79
33	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. <i>Circulation</i> , 2008, 117, 1101-1120.	1.6	76
34	Events in the cardiac arrhythmia suppression trial (CAST): Mortality in the entire population enrolled. <i>Journal of the American College of Cardiology</i> , 1991, 18, 14-19.	1.2	71
35	Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. <i>American Heart Journal</i> , 2005, 149, 645-649.	1.2	67
36	Programmed electrical stimulation studies for ventricular tachycardia induction in humans. I. The role of ventricular functional refractoriness in tachycardia induction. <i>Journal of the American College of Cardiology</i> , 1986, 8, 567-575.	1.2	66

#	ARTICLE	IF	CITATIONS
37	ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004, 44, 475-495.	1.2	65
38	Atrial fibrillation: a risk factor for increased mortality—an AVID registry analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 267-273.	0.6	60
39	Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. <i>Annals of Emergency Medicine</i> , 2017, 69, 562-571.e2.	0.3	51
40	The Optimal Anti-Coagulation for Enhanced-Risk Patients Postâ€Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018, 197, 124-132.	1.2	50
41	Atrial Fibrillation Detection and R-Wave Synchronization by Metrix Implantable Atrial Defibrillator. <i>Circulation</i> , 1999, 99, 1446-1451.	1.6	44
42	Alternative endpoints for mortality in studies of patients with atrial fibrillation: The AFFIRM study experience. <i>Heart Rhythm</i> , 2004, 1, 531-537.	0.3	43
43	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1207-1218.	0.8	43
44	Character of adverse effects of prophylactic lidocaine in the coronary care unit. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 71-80.	2.3	42
45	Mexiletine-quinidine combination: Electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. <i>Journal of the American College of Cardiology</i> , 1987, 10, 1149-1156.	1.2	39
46	Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: The TRENDS study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2006, 15, 9-14.	0.6	38
47	Antiarrhythmic efficacy of propranolol: Comparison of low and high serum concentrations. <i>Journal of the American College of Cardiology</i> , 1986, 8, 959-965.	1.2	34
48	Treating the right patient at the right time: An innovative approach to the management of atrial fibrillation. <i>Canadian Journal of Cardiology</i> , 2008, 24, 195-198.	0.8	32
49	Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 420-425.	1.2	29
50	Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort. <i>Circulation</i> , 2009, 120, 1436-1443.	1.6	29
51	The AFFIRM trial: main trial and substudies-what can We expect?. , 2000, 4, 171-176.		28
52	Drug therapy for ventricular tachyarrhythmias: How many electropharmacologic trials are appropriate?. <i>Journal of the American College of Cardiology</i> , 1991, 17, 391-396.	1.2	27
53	Propafenone-Induced Torsade de Pointes: Cross-Reactivity with Quinidine. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991, 14, 1568-1570.	0.5	27
54	Programmed electrical stimulation studies for ventricular tachycardia induction in humans. II. Comparison of indwelling electrode catheter and daily catheter replacement. <i>Journal of the American College of Cardiology</i> , 1986, 8, 576-581.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Rate Control vs Rhythm Control Strategies in Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 125-138.	1.6	26
56	Events in the cardiac arrhythmia suppression trial (CAST): Mortality in patients surviving open label titration but not randomized to double-blind therapy. <i>Journal of the American College of Cardiology</i> , 1991, 18, 20-28.	1.2	25
57	Heart rate and adverse outcomes in patients with atrial fibrillation: A combined AFFIRM and AF-CHF substudy. <i>Heart Rhythm</i> , 2016, 13, 54-61.	0.3	25
58	Dual Site Right Atrial Pacing can Improve the Impact of Standard Dual Chamber Pacing on Atrial and Ventricular Mechanical Function in Patients with Symptomatic Atrial Fibrillation: Further Observations from the Dual Site Atrial Pacing for Prevention of Atrial Fibrillation Trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2005, 12, 177-187.	0.6	24
59	Rhythm versus Rate Control Trials in Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S35-S39.	0.8	23
60	Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. <i>European Heart Journal</i> , 2008, 29, 1873-1880.	1.0	22
61	Blood Pressure and Atrial Fibrillation: A Combined AF-CHF and AFFIRM Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 509-514.	0.8	22
62	Selection of Endpoints in Atrial Fibrillation Studies. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, S47-52.	0.8	21
63	Total Atrioventricular Nodal Ablation Increases Atrial Fibrillation Burden in Patients with Paroxysmal Atrial Fibrillation Despite Continuation of Antiarrhythmic Drug Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 1296-1301.	0.8	21
64	Anticoagulation in atrial fibrillation: A contemporary viewpoint. <i>Heart Rhythm</i> , 2007, 4, S34-S39.	0.3	20
65	Cardioversion of Atrial Fibrillation for Maintenance of Sinus Rhythm: A Road to Nowhere. <i>Circulation</i> , 2009, 120, 1444-1452.	1.6	20
66	Clinical and Electrophysiologic Predictors of Ventricular Tachyarrhythmia Recurrence in Patients with Implantable Cardioverter Defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 492-498.	0.8	18
67	Randomized Controlled Trial of Fixed Rate Versus Rate Responsive Pacing After Radiofrequency Atrioventricular Junction Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 1163-1170.	0.8	18
68	Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009, 25, 25-29.	0.6	18
69	Therapeutic Considerations in Applying Rate Control Therapy for Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 11-17.	0.8	17
70	Comparison of Management Patterns and Clinical Outcomes in Patients With Atrial Fibrillation in Canada and the United States (from the Analysis of the Atrial Fibrillation Follow-up Investigation of) <i>Tj ETQq0 0 0 rg87 /Overlook 10 Tf 5</i>	0.7	16
71	Bleeding While Starting Anticoagulation for Thromboembolism Prophylaxis in Elderly Patients With Atrial Fibrillation. <i>Circulation</i> , 2007, 115, 2684-2686.	1.6	16
72	Systolic blood pressure and mortality in patients with atrial fibrillation and heart failure: insights from the <sc>AFFIRM</sc> and <sc>AF-CHF</sc> studies. <i>European Journal of Heart Failure</i> , 2014, 16, 1168-1174.	2.9	16

#	ARTICLE	IF	CITATIONS
73	Procainamide, disopyramide and quinidine: Discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia. <i>Journal of the American College of Cardiology</i> , 1987, 9, 882-889.	1.2	15
74	Quantification of three lidocaine metabolites and their conjugates. <i>Pharmaceutical Research</i> , 1990, 07, 504-507.	1.7	15
75	Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function. <i>American Heart Journal</i> , 1988, 115, 1030-1036.	1.2	14
76	Contribution of quinidine metabolites to electrophysiologic responses in human subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 352-358.	2.3	14
77	A randomized clinical trial of the noninvasive and invasive approaches to drug therapy for ventricular tachycardia: Long-term follow-up of the calgary trial. <i>Progress in Cardiovascular Diseases</i> , 1996, 38, 377-384.	1.6	14
78	Long-term Reproducibility of Ventricular Tachycardia Induction in Patients With Implantable Cardioverter/Defibrillators. <i>Circulation</i> , 1995, 91, 2605-2613.	1.6	14
79	Frequency and Outcomes of Postrandomization Atrial Tachyarrhythmias in the Resynchronization/Defibrillation in Ambulatory Heart Failure Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	13
80	Lenient Versus Strict Rate Control in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 58, 950-952.	1.2	12
81	Idiopathic atrial fibrillation: a rose by any other name?. <i>Europace</i> , 2012, 14, 151-152.	0.7	11
82	The Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1566-1569.	0.8	11
83	Amiloride-quinidine interaction: Adverse outcomes. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 659-667.	2.3	10
84	Pharmacologic approaches to rhythm versus rate control in atrial fibrillation—where are we now?. <i>International Journal of Cardiology</i> , 2006, 110, 301-312.	0.8	10
85	Death and Digoxin: Stop Me If You've Heard This One Before. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1145-1147.	0.8	9
86	An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. <i>CJC Open</i> , 2019, 1, 198-205.	0.7	9
87	A Critical Perspective on the Role of Catheter Ablation in Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1150-1157.	0.8	8
88	Concentration-response relationships of disopyramide in patients with ventricular tachycardia. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 542-547.	2.3	7
89	Are there alternatives to mortality as an endpoint in clinical trials of atrial fibrillation?. <i>Heart Rhythm</i> , 2004, 1, 41-44.	0.3	6
90	The Euro Heart Survey on atrial fibrillation: a picture and a thousand wordsThe opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 2356-2357.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Medical management of atrial fibrillation. <i>Current Cardiology Reports</i> , 2006, 8, 323-329.	1.3	6
92	Pharmacologic Therapy in Patients with Ventricular Tachyarrhythmias. <i>Cardiology Clinics</i> , 1993, 11, 65-82.	0.9	5
93	Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. <i>North American Society of Pacing and Electrophysiology. Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 345-364.	0.6	5
94	It's Health Care Delivery, Stupid: Implementing the New Canadian Cardiovascular Society Atrial Fibrillation Treatment Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, 14-18.	0.8	5
95	Dose-related cardiac electrophysiologic effects of sulfapyrazone. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 166-173.	2.3	4
96	Quinidine pharmacodynamics in patients with arrhythmia: Effects of left ventricular function. <i>Journal of the American College of Cardiology</i> , 1995, 25, 989-994.	1.2	4
97	Risks of Overinterpreting Interim Data. <i>Circulation</i> , 2018, 137, 206-209.	1.6	4
98	Some recent randomized clinical trials in the management of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 9, 223-228.	0.6	3
99	Atrial fibrillation: Challenges and opportunities. <i>Canadian Journal of Cardiology</i> , 2006, 22, 21C-26C.	0.8	3
100	Transvenous Radiofrequency Catheter Ablation for Atrial Flutter and Atrial Fibrillation. <i>Circulation</i> , 2006, 114, 1670-1672.	1.6	3
101	What is the best method of detecting atrial fibrillation in people aged 65 years and older?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 138-139.	3.3	2
102	Targeted Therapeutic Drug Monitoring for Direct Oral Anticoagulants: What Is Its Potential Place and Can It Limit Black Swan Events?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1393-1395.	0.8	2
103	Divergence of endocardial QT interval components during programmed electrical stimulation including observations during induction of sustained ventricular tachyarrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997, 1, 23-31.	0.6	1
104	Conduction time oscillations precede the spontaneous termination of human atrioventricular reciprocating tachycardia. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 231-239.	0.6	1
105	Overview of Atrial Fibrillation Trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 149-155.	0.9	1
106	In the wake of the AFFIRM trial: what we still don't know about the management of atrial fibrillation and where we need to go. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 130-135.	0.9	1
107	Economics of Managing Atrial Fibrillation: Broadening the Focus to Include Efficiency. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 634-635.	0.8	1
108	Temporal Patterns and Predictors of Rate vs Rhythm Control in Patients Attending a Multidisciplinary Atrial Fibrillation Clinic. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1247.e7-1247.e13.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Rate Control Versus Rhythm Control in the ORBIT-AF Registry. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 230-232.	1.3	1
110	Surveillance for Outcomes Selected as Atrial Fibrillation Quality Indicators in Canada: 10-Year Trends in Stroke, Major Bleeding, and Heart Failure. <i>CJC Open</i> , 2021, 3, 609-618.	0.7	1
111	Review of Recent Trials of Medical Therapy for Atrial Fibrillation. , 2008, , 147-168.		1
112	Amiloride: Effects on Right and Left Ventricular Function in Patients with Inducible Sustained Ventricular Tachycardia. <i>American Journal of Noninvasive Cardiology</i> , 1992, 6, 184-191.	0.1	0
113	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2004, 8, 145-146.	0.0	0
114	Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 132-133.	3.3	0
115	Management of Atrial Fibrillation in Elderly Patients. <i>The American Journal of Geriatric Cardiology</i> , 2005, 14, 54-55.	0.7	0
116	Classification of atrial fibrillation: reply. <i>European Heart Journal</i> , 2006, 27, 621-622.	1.0	0
117	Change is coming: Lead, follow, or get out of the way. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009, 25, 163-165.	0.6	0
118	Response to Letter by Willey. <i>Stroke</i> , 2010, 41, .	1.0	0
119	More on the blockade of neural and exogenous noradrenaline in vascular tissue. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 25, 837-840.	1.2	0
120	Results of Clinical Trials on Atrial Fibrillation. , 2004, , 895-900.		0